...
首页> 外文期刊>World Journal of Gastroenterology >Altered distribution of regulatory lymphocytes by oral administration of soy-extracts exerts a hepatoprotective effect alleviating immune mediated liver injury, non-alcoholic steatohepatitis and insulin resistance
【24h】

Altered distribution of regulatory lymphocytes by oral administration of soy-extracts exerts a hepatoprotective effect alleviating immune mediated liver injury, non-alcoholic steatohepatitis and insulin resistance

机译:口服大豆提取物可改变调节性淋巴细胞的分布,可起到保护肝脏的作用,减轻免疫介导的肝损伤,非酒精性脂肪性肝炎和胰岛素抵抗

获取原文
           

摘要

AIM: To determine the immune-modulatory and the hepatoprotective effects of oral administration of two soy extracts in immune mediated liver injury and non-alcoholic steatohepatitis (NASH). METHODS: Two soy extracts, M1 and OS, were orally administered to mice with concanavalin A (ConA) immune-mediated hepatitis, to high-fat diet (HFD) mice and to methionine and choline reduced diet combined with HFD mice. Animals were followed for disease and immune biomarkers. RESULTS: Oral administration of OS and M1 had an additive effect in alleviating ConA hepatitis manifested by a decrease in alanine aminotransferase and aspartate aminotransferase serum levels. Oral administration of the OS and M1 soy derived fractions, ameliorated liver injury in the high fat diet model of NASH, manifested by a decrease in hepatic triglyceride levels, improvement in liver histology, decreased serum cholesterol and triglycerides and improved insulin resistance. In the methionine and choline reduced diet combined with the high fat diet model, we noted a decrease in hepatic triglycerides and improvement in blood glucose levels and liver histology. The effects were associated with reduced serum tumor necrosis factor alpha and alteration of regulatory T cell distribution. CONCLUSION: Oral administration of the combination of OS and M1 soy derived extracts exerted an adjuvant effect in the gut-immune system, altering the distribution of regulatory T cells, and alleviating immune mediated liver injury, hyperlipidemia and insulin resistance.
机译:目的:确定口服两种大豆提取物对免疫介导的肝损伤和非酒精性脂肪性肝炎(NASH)的免疫调节和肝保护作用。方法:将两种大豆提取物M1和OS口服给予伴刀豆球蛋白A(ConA)免疫介导的肝炎的小鼠,高脂饮食(HFD)小鼠以及蛋氨酸和胆碱减低饮食与HFD小鼠组合。跟踪动物的疾病和免疫生物标记。结果:口服OS和M1在减轻ConA肝炎方面具有累加作用,其表现为丙氨酸转氨酶和天冬氨酸转氨酶血清水平降低。口服OS和M1大豆衍生成分可改善NASH高脂饮食模型中的肝损伤,其表现为肝甘油三酸酯水平降低,肝脏组织学改善,血清胆固醇和甘油三酸酯降低以及胰岛素抵抗增强。在蛋氨酸和胆碱减少饮食与高脂饮食模型相结合的研究中,我们注意到肝甘油三酯减少,血糖水平和肝脏组织学改善。这些作用与血清肿瘤坏死因子α降低和调节性T细胞分布改变有关。结论:口服OS和M1大豆提取物的组合可在肠道免疫系统中发挥辅助作用,改变调节性T细胞的分布,并减轻免疫介导的肝损伤,高脂血症和胰岛素抵抗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号